| Severe acute respiratory syndrome coronavirus 2− specific antibody responses in coronavirus disease patients NMA Okba, MA Müller, W Li, C Wang, CH GeurtsvanKessel, VM Corman, ... Emerging infectious diseases 26 (7), 1478, 2020 | 1617 | 2020 |
| A human monoclonal antibody blocking SARS-CoV-2 infection C Wang, W Li, D Drabek, NMA Okba, R van Haperen, ADME Osterhaus, ... Nature communications 11 (1), 2251, 2020 | 1271 | 2020 |
| Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability PJM Brouwer, TG Caniels, K van der Straten, JL Snitselaar, Y Aldon, ... Science 369 (6504), 643-650, 2020 | 1159 | 2020 |
| Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model B Rockx, T Kuiken, S Herfst, T Bestebroer, MM Lamers, BB Oude Munnink, ... Science 368 (6494), 1012-1015, 2020 | 1008 | 2020 |
| Phenotype and kinetics of SARS-CoV-2–specific T cells in COVID-19 patients with acute respiratory distress syndrome D Weiskopf, KS Schmitz, MP Raadsen, A Grifoni, NMA Okba, H Endeman, ... Science immunology 5 (48), eabd2071, 2020 | 937 | 2020 |
| Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) JJA van Kampen, DAMC van de Vijver, PLA Fraaij, BL Haagmans, ... Nature communications 12 (1), 267, 2021 | 671 | 2021 |
| SARS-CoV-2 is transmitted via contact and via the air between ferrets M Richard, A Kok, D de Meulder, TM Bestebroer, MM Lamers, NMA Okba, ... Nature communications 11 (1), 3496, 2020 | 486 | 2020 |
| An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment CH GeurtsvanKessel, NMA Okba, Z Igloi, S Bogers, CWE Embregts, ... Nature communications 11 (1), 3436, 2020 | 368 | 2020 |
| An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels BL Haagmans, JMA Van Den Brand, VS Raj, A Volz, P Wohlsein, ... Science 351 (6268), 77-81, 2016 | 289 | 2016 |
| Convalescent plasma for COVID-19. A randomized clinical trial A Gharbharan, CCE Jordans, C Geurtsvankessel, JG den Hollander, ... MEDRxiv, 2020.07. 01.20139857, 2020 | 279 | 2020 |
| Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants JJA van Kampen, DAMC van de Vijver, PLA Fraaij, BL Haagmans, ... MedRxiv, 2020.06. 08.20125310, 2020 | 249 | 2020 |
| SARS-CoV-2 specific antibody responses in COVID-19 patients NMA Okba, MA Müller, W Li, C Wang, CH GeurtsvanKessel, VM Corman, ... MedRxiv, 2020.03. 18.20038059, 2020 | 235 | 2020 |
| Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection A Gharbharan, CCE Jordans, C GeurtsvanKessel, JG den Hollander, ... Nature communications 12 (1), 3189, 2021 | 170 | 2021 |
| Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial T Koch, C Dahlke, A Fathi, A Kupke, V Krähling, NMA Okba, S Halwe, ... The Lancet Infectious Diseases 20 (7), 827-838, 2020 | 158 | 2020 |
| Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection PJM Brouwer, M Brinkkemper, P Maisonnasse, N Dereuddre-Bosquet, ... Cell 184 (5), 1188-1200. e19, 2021 | 155 | 2021 |
| A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies C Wang, R van Haperen, J Gutiérrez-Álvarez, W Li, NMA Okba, ... Nature communications 12 (1), 1715, 2021 | 148 | 2021 |
| Susceptibility of rabbits to SARS-CoV-2 AZ Mykytyn, MM Lamers, NMA Okba, TI Breugem, D Schipper, ... Emerging Microbes & Infections 10 (1), 1-7, 2021 | 143 | 2021 |
| Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein I Widjaja, C Wang, R van Haperen, J Gutiérrez-Álvarez, B van Dieren, ... Emerging microbes & infections 8 (1), 516-530, 2019 | 127 | 2019 |
| Sensitive and specific detection of low-level antibody responses in mild Middle East respiratory syndrome coronavirus infections NMA Okba, VS Raj, IVY Widjaja, CH GeurtsvanKessel, E De Bruin, ... Emerging infectious diseases 25 (10), 1868, 2019 | 89 | 2019 |
| Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination A Tscherne, JH Schwarz, C Rohde, A Kupke, G Kalodimou, L Limpinsel, ... Proceedings of the National Academy of Sciences 118 (28), e2026207118, 2021 | 77 | 2021 |
